Resmed Inc (NYSE: RMD) has reported earnings for its second fiscal quarter (ending December 31) of $2.35 versus $1.42 for the same period a year ago — an increase of 65%. For the latest four quarters through December 31, E.P.S. were $8.50 versus $6.05 for the same period a year ago — an increase of 40%.
Recent Price Action
Resmed Inc (NYSE: RMD) stock increased 1.9% on 1/30/25. The shares closed at $257.65. Moreover, exceptionally high trading volume at 227% of normal accompanied the advance. The stock has been strong relative to the market over the last nine months and has risen 4.2% during the last week.
Current PriceTarget Research Rating
Resmed has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Resmed has a poor Appreciation Score of 26 but a good Power Rating of 74, triggering the Neutral Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment